-
Mashup Score: 3Outside the Guidelines: Denosumab Overuse in Prostate Cancer - 2 month(s) ago
Many men with castration-sensitive prostate cancer receive the bone-modifying agent to prevent skeletal-related events, but that practice is not recommended and costs Medicare millions annually.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 81Memorial Sloan Kettering Study Exposes $43 Million Medicare Oversp… - 2 month(s) ago
A recent study by Memorial Sloan Kettering highlights the financial and clinical implications of Denosumab overuse in prostate cancer treatment, emphasizing the need for guideline adherence.
Source: medriva.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Outside the Guidelines: Denosumab Overuse in Prostate Cancer - 2 month(s) ago
Many men with castration-sensitive prostate cancer receive the bone-modifying agent to prevent skeletal-related events, but that practice is not recommended and costs Medicare millions annually.
Source: www.medscape.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Practice Consolidation Among US Medical Oncologists, 2015-2022 - 2 month(s) ago
PURPOSE Health care consolidation has significantly affected cancer care delivery, with oncology practices undergoing substantial consolidation over the past two decades. This study investigates practice consolidation trends among medical oncologists (MOs), factors associated with consolidation, and changes in MO geographic distribution. METHODS Medicare data from 2015 to 2022 were used to assess MO practice consolidation in hospital referral regions (HRRs), linked with regional health care market data and physician demographics. The Herfindahl-Hirschman Index (HHI) was used to measure consolidation, and the Gini coefficient was used to measure MO distribution across counties. Multivariable linear regression explored factors associated with MO practice consolidation. RESULTS Between 2015 and 2022, the number of MOs increased by 14.5% (11,727-13,433), whereas the number of MO practices decreased by 18.0% (2,774-2,276). The mean number of MOs per practice increased by 40% (4.26-5.95; P <
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
This systematic review of 18 studies examines the association between financial incentives offered to oncologists and practice patterns in delivery of care to patients with cancer.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Important Research Data Request & Access Policy Changes | CMS - 3 month(s) ago
The Centers for Medicare & Medicaid Services (CMS) is announcing two changes to the current research data request and access policies. To review the current CMS Research Identifiable File (RIF) policies please click here (PDF).
Source: www.cms.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
This cohort study assesses the incidence of severe and very severe hypocalcemia in female dialysis-dependent patients aged 65 years or older receiving denosumab compared with oral bisphosphonates.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer - 4 month(s) ago
AbstractBackground. Bone-modifying agent (BMA) therapy is recommended for metastatic castration-resistant prostate cancer but not metastatic castration-sensitiv
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 42Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer - 4 month(s) ago
PURPOSE Bone-modifying agents (BMAs) do prevent skeletal-related events among patients with castration-sensitive prostate cancer (CSPC), but many patients receive BMAs unnecessarily. The costs to Medicare from overuse have not been assessed. METHODS We used linked SEER-Medicare data 2011-2015 to measure the frequency and number of doses of zoledronic acid (ZA) and denosumab received during CSPC (between diagnosis and initiation of metastatic, castration resistant prostate cancer therapy). We estimated excess BMA among patients who received BMA therapy for CSPC and did not have an indication for osteoporosis fracture prevention. We used the Medicare fee schedule for drug prices and peer-reviewed sources to estimate adverse event frequencies and costs. RESULTS Median CSPC duration was 387 days (IQR, 253-573), during which time 42% of patients received ≥one dose of denosumab (mean doses, 7) and 18% received ≥one dose of ZA (mean doses, 7). Thirty-eight percent of those receiving denosumab
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis - 5 month(s) ago
Denosumab has been approved in the US for skeletal-related event (SRE) prevention in bone-metastatic prostate cancer on the basis of a phase III clinical trial in which denosumab reduced SREs relat…
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet
Thanks to @Medscape for covering our recent study of wasted spending on bone agent overuse in prostate cancer! https://t.co/XnoSiz0qPg Thread on study findings below https://t.co/gW60elFcyi